Glucose Metabolism Disorders
Conditions
Keywords
GIP, GIP receptor antagonist
Brief summary
Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.
Detailed description
Aim: To evaluate the role of GIPR signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring GIP fragment (GIP-A), which antagonises the GIPR. Eighteen healthy men (age 18-70 years, BMI 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin\[9-39\], C) GIP-A + Exendin\[9-39\], or D) saline (placebo).
Interventions
GIP receptor antagonist + GLP-1 receptor antagonist
OTHERGIP-A
GIP-A (GIP receptor antagonist)
Exendin\[9-39\]
OTHERPlacebo
Saline (9mg/mL)
Sponsors
University of Copenhagen
University Hospital, Gentofte, Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Normal kidney function, liver function and hemoglobin levels.
Exclusion criteria
* Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin levels | 240 minutes | Serum insulin AUC (area under the curve) |
Countries
Denmark
Outcome results
None listed